
FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Opens the Door to a New Standard ...
Options for later lines of neuroendocrine tumor treatment were limited until the FDA approved cabozantinib (Cabometyx), which helped change the narrative for adult and pediatric patients aged 12 years or older with previously treated, unresectable, locally …